The GLP-1 receptor agonist market is focused on therapies widely used for managing type 2 diabetes and obesity. These drugs work by mimicking the natural GLP-1 hormone, which helps regulate blood sugar, improve insulin secretion, slow digestion, and reduce appetite. Rising global rates of diabetes, obesity, and related lifestyle disorders are key drivers for market growth. In addition to blood sugar control, GLP-1 receptor agonists have shown benefits in weight management and cardiovascular health, making them increasingly popular among patients and healthcare providers.
According to Fortune Business Insights, the global GLP-1 receptor agonist market was valued at USD 52.08 billion in 2024 and is projected to grow from USD 62.83 billion in 2025 to USD 186.64 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.8% during the forecast period. In 2024, North America dominated the market with a 55.51% share.
In June 2024, Novo Nordisk A/S entered a strategic collaboration with Biosplice Therapeutics, Inc., aiming to develop a new drug candidate for diabetes treatment—highlighting the industry's commitment to pioneering R&D.
The accelerating prevalence of type 2 diabetes and obesity worldwide is a driving force behind market expansion. Coupled with continuous advancements in drug formulations and the extension of therapeutic applications beyond diabetes—such as for obesity and potential cardiovascular indications—the market is poised for exponential growth. Innovations like oral formulations, combination therapies, strategic partnerships, and a shift towards personalized medicine are further fueling momentum.
A prominent challenge remains the shortage of GLP-1 agonists, brought on by soaring demand across obesity and diabetes treatments. Nevertheless, manufacturers are actively addressing supply issues by expanding their production capacities.
The Fortune Business Insights report delivers a comprehensive breakdown—spanning market segments such as drug type, route of administration, age group, indication, distribution channel, and regional analysis. It includes a detailed forecast alongside assessments of current market dynamics, the impact of COVID-19, and evolving trends. Competitive market shares, segmentation insights, and growth catalysts are all included.